Save this page
Save this page

My Saved Pages

  • Saved page.

My Saved Courses

  • Saved page.

Recently visited

  • Saved page.

Dr Marie Boyd


Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

Dr Marie Boyd joined SIPBS from the CRUK Beatson Laboratories in July 2009 as a SULSA Reader in Translational Biology. Dr Boyd was awarded a CRUK Senior Cancer Research Fellowship in 2005 to investigate targeted radionuclide therapy for cancer. Targeted radionuclide therapy utilised radiation like a drug, that is molecules which are accrued specifically in tumours have a radioactive molecule attached, and once the radiopharmaceutical is injected into the body and it gets concentrated only in tumour cells. This results in irradiation specifically to tumour cells sparing normal tissues and thus reduction of toxic side effects. Our research group focuses on expansion of this form of radiotherapy to more tumour types by investigation and development of novel radiopharmaceuticals and targets as well as by adopting gene therapy techniques.

The group also investigates the basic biology of cellular response to radiotherapy and have a large area of research into combining radiotherapy with novel and existing drugs and interrogation of cell signaling and mechanisms using traditional and “Omics” based approaches. The Boyd group have already translated some therapeutic schemes into clinical trial and other promising schemes based upon repurposing of existing drugs, are underway with Industrial partners including AstraZeneca.

 Since the transfer to Strathclyde, the group has established several cross-disciplinary links within the TIC themes in areas of advanced Sciences and Technologies, Bionanotechnology, and Health Technologies at Strathclyde. These collaborations are formed around the need to establish multidisciplinary approaches to the development of cancer therapy. Our work fosters the marriage of cancer biology and radiobiology with platform technologies such as Laser Plasma Wakefield Accelerators, microfluidics, biogels and the combinations of novel and existing drugs and nanomaterials in the SU pipeline with chemo- and radiotherapy produced by a variety of radiation sources. The group will also be integral to the new TIC building hosting the SCAPA (Scottish centre for applied particle accelerators) facility. This research environment is a resource which is unique to Strathclyde University.

The Group is highly active within the recently established RICAS (Research In Cancer at Strathclyde) initiative, has been highly successful in achieving multi-disciplinary, Industry and clinical linked funding. The breadth of research has also recently expanded by involvement in the SIPBS led multi-university programme in pharmacoepidemiology. With our partners we are interrogating prescribing databases to interrogate questions which may lead to the development of better and more personalised cancer therapeutics. The group is also involved with several drug discovery programmes within and outwith the university and has developed phenotypic assay cascades to aid these programmes.

Dr Boyd's group is highly active in the research, industrial and clinical arena and the lab hosts senior fellows, Post docs, PhD students, research assistants, undergraduate and students from within SIPBS and from other University Departments (Physics, chemistry, EEE). The Boyd group will also host vertically Integrated Studentships (VIPs) within the lab, which are being run in collaboration with Chemistry and EEE and we are becoming partners in the Laser Plasma Accelerator Doctoral training centre spearheaded by the university.



Untargeted metabolomics profiling of an 80.5 km simulated treadmill ultramarathon
Howe Christopher C. F., Alshehri Ahmed, Muggeridge David, Mullen Alexander B., Boyd Marie, Spendiff Owen, Moir Hannah J., Watson David G.
Metabolites Vol 8, (2018)
Lysosomotropism depends on glucose : a chloroquine resistance mechanism
Gallagher Laura E, Radhi Ohood A, Abudullah Mahmud O, McCluskey Anthony G, Boyd Marie, Chan Edmond Y W
Cell Death and Disease Vol 8, (2017)
Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers
Anthony Nahoum G., Baiget Jessica, Berretta Giacomo, Boyd Marie, Breen David, Edwards Joanne, Gamble Carly, Gray Alexander I., Harvey Alan L., Hatziieremia Sophia, Ho Ka Ho, Huggan Judith K., Lang Stuart, Llona-Minguez Sabin, Luo Jia Lin, McIntosh Kathryn, Paul Andrew, Plevin Robin J., Robertson Murray N., Scott Rebecca, Suckling Colin J., Sutcliffe Oliver Brook, Young Louise C., MacKay Simon P.
Journal of Medicinal Chemistry Vol 60, pp. 7043-7066, (2017)
Laser-plasma generated very high energy electrons (VHEEs) in radiotherapy
Kokurewicz K., Welsh G. H., Brunetti E., Wiggins S. M., Boyd M., Sorensen A., Chalmers A., Schettino G., Subiel A., DesRosiers C., Jaroszynski D. A.
Proceedings of SPIE 7982, Smart Sensor Phenomena, Technology, Networks, and Systems 2011 Vol 10239, (2017)
On-chip formation of 3D spheroids for patient-derived tissue screening
Christ T., Payne S., Yan Y., Ren J., Edwards J., Boyd M., Zagnoni M.
20th International Conference on Miniaturized Systems for Chemistry and Life Sciences (MicroTAS 2016), pp. 577-578, (2016)
From emulsion to single-phase microfluidics : an integrated approach to culture and perfusion of multicellular spheroids
McMillan Kay S, Boyd Marie, Zagnoni Michele
20th International Conference on Miniaturized Systems for Chemistry and Life Sciences (MicroTAS 2016), pp. 399-400, (2016)

more publications

Professional activities

Duquesne University
Visiting researcher
Dusquene University
Visiting researcher
Paediatric Formulation of Medicines
Austrian Drug Screening Institute
Visiting researcher
Medicinal Chemistry : Current Research (Journal)
Peer reviewer
International preventative research Institute (External organisation)

more professional activities


Oral thin film drug delivery systems allowing complex release patternsfor use in healthcare (SE HGSP)
Mullen, Alexander (Principal Investigator) Boyd, Marie (Co-investigator)
Period 15-Nov-2017 - 30-Aug-2018
Laser-driven radiation beamlines at SCAPA (EPSRC Capital Equipment Portfolio)
McKenna, Paul (Principal Investigator) Boyd, Marie (Co-investigator) Hidding, Bernhard (Co-investigator) Jaroszynski, Dino (Co-investigator) McArthur, Stephen (Co-investigator) Sheng, Zheng-Ming (Co-investigator)
We propose to create new capability and capacity for collaborative high power laser-plasma research to underpin the development and application of laser-driven radiation sources, using three new beamlines and experiment stations at the Scottish Centre for the Application of Plasma-based Accelerators, SCAPA. Each of the beamlines will be configured in a unique way and with a focus on a specific category of laser-plasma interactions and secondary sources, to create a complementary suite of dedicated beamlines. This approach is required to enable the development and optimisation of laser-plasma sources from the realms of scientific investigation to real-world applications. It enables long-term investment in the optimisation and stabilisation of the beams and largely eliminates downtime for rebuilding experiments, thus enabling efficient and effective use of high power laser beam time.

The equipment will support an extensive research portfolio in laser-plasma physics and multidisciplinary applications, with an emphasis on radiation sources and healthcare applications. The unique properties of laser-driven radiation sources make them attractive both as tools for science (e.g. femtosecond X-ray sources for probing the structure of matter) and for applications in a variety of sectors including: healthcare (e.g. imaging and radiotherapy); industry (e.g. penetrative probing and assay) and energy (e.g. testing the integrity of stored nuclear waste). The strategic development of this field requires a balanced programme of dedicated university-scale and leading-edge national laser facilities. The proposed beamlines will complement existing and planned expansion of national facilities at the Central Laser Facility, providing new capability and capacity to enable UK research groups to remain at the forefront of this research area and help promote international collaboration.

The research will be performed collaboratively with groups from across the UK and sustained mainly through collaborative research grants. The new suite of beamlines will promote exchanges between academia and industry, and enable engagement of the UK research community with large international projects, such as the Extreme Light Infrastructure, ELI. It will also provide a unique interdisciplinary training platform for researchers.
Period 01-Apr-2017 - 31-Mar-2020
BBSRC Doctoral Training Grant (DTG) | McGinely, Nicola Louise
Boyd, Marie (Principal Investigator)
Period 01-Oct-2011 - 29-Apr-2016
Epsrc Doctoral Training Grant | McMillan, Kay
Zagnoni, Michele (Principal Investigator) Boyd, Marie (Co-investigator) McMillan, Kay (Research Co-investigator)
Period 01-Oct-2012 - 23-Jan-2017
Lab in a bubble
Jaroszynski, Dino (Principal Investigator) Boyd, Marie (Co-investigator) Brunetti, Enrico (Co-investigator) Ersfeld, Bernhard (Co-investigator) Hidding, Bernhard (Co-investigator) McKenna, Paul (Co-investigator) Noble, Adam (Co-investigator) Sheng, Zheng-Ming (Co-investigator) Vieux, Gregory (Co-investigator) Welsh, Gregor (Co-investigator) Wiggins, Samuel (Co-investigator)
"The lab in a bubble project is a timely investigation of the interaction of charged particles with radiation inside and in the vicinity of relativistic plasma bubbles created by intense ultra-short laser pulses propagating in plasma. It builds on recent studies carried out by the ALPHA-X team of coherent X-ray radiation from the laser-plasma wakefield accelerator and high field effects where radiation reaction becomes important. The experimental programme will be carried out using high power lasers and investigate new areas of physics where single-particle and collective radiation reaction and quantum effects become important, and where non-linear coupling and instabilities between beams, laser, plasma and induced fields develop, which result in radiation and particle beams with unique properties. Laser-plasma interactions are central to all problems studied and understanding their complex and often highly non-linear interactions gives a way of controlling the bubble and beams therein. To investigate the rich range of physical processes, advanced theoretical and experimental methods will be applied and advantage will be taken of know-how and techniques developed by the teams. New analytical and numerical methods will be developed to enable planning and interpreting results from experiments. Advanced experimental methods and diagnostics will be developed to probe the bubble and characterise the beams and radiation. An important objective will be to apply the radiation and beams in selected proof-of-concept applications to the benefit of society.
The project is involves a large group of Collaborators and Partners, who will contribute to both theoretical and experimental work. The diverse programme is managed through a synergistic approach where there is strong linkage between work-packages, and both theoretical and experiential methodologies are applied bilaterally: experiments are informed by theory at planning and data interpretation stages, and theory is steered by the outcome of experimental studies, which results in a virtuous circle that advances understanding of the physics inside and outside the lab in a bubble. We also expect to make major advances in high field physics and the development of a new generation of compact coherent X-ray sources."
Period 01-Apr-2016 - 31-Mar-2020
Development of oral wafers as medicines for use in the treatment of pain in children with cancer
Mullen, Alexander (Principal Investigator) Boyd, Marie (Co-investigator)
Period 01-Apr-2016 - 31-Mar-2018

more projects


Strathclyde Institute of Pharmacy and Biomedical Sciences
Hamnett Wing John Arbuthnott Building

Location Map

View University of Strathclyde in a larger map